TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of a Patient Education Video

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Cancer patients scheduled for HSCT~Exclusion Criteria:~* Patients who have received HSCT previously~* Patients who do not speak English

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Video (Type: EXPERIMENTAL): Patients will view the 23-minute Guide to Stem Cell Transplantation video depicting the HSCT experience
- FAQ Sheet (Type: ACTIVE_COMPARATOR): Patients will receive HSCT FAQ sheet developed by the NCI at the NIH

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Timolol for the Prevention of Proliferation of Infantile Hemangioma (TiPPIH Trial)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Babies admitted to NICU or seen in follow clinic that have a diagnosis of hemangioma that is verified by Principal Investigator (PI) or Co-Principal Investigators.~Exclusion Criteria:~* Babies with PHACES (Posterior fossa, Hemangioma, Arterial lesions, Cardiac abnormalities, Eye abnormalities) syndrome~* Babies with cardiac conditions that may predispose to heart block~* Babies with persistent hypoglycemia~* Babies on medications that may interact with beta blockers~* Babies who are hemodynamically unstable and are requiring pressors to maintain blood pressure~* Babies who are on systemic corticosteroid therapy

- Gender: ALL
- Minimum Age: None
- Maximum Age: 6 Months
- Healthy Volunteers: f

Study Arms:
- Timolol (Type: EXPERIMENTAL): Application of 1-2 drops of Timolol maleate 0.5% ophthalmic aqueous solution to hemangioma twice daily.
- Placebo (Type: PLACEBO_COMPARATOR): Application of 1-2 drops of placebo gel twice daily to hemangioma.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Feeding Different Levels of Docosahexaenoic Acid to Pre-School Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Child is 3 years of age ± 90 days~* Weight for length is within 10th to 90th percentile as plotted on WHO growth charts~* Parent/caregiver reports that child consumes at least 6 oz of cow milk or cow milk-based beverages on a daily basis~* Parent is willing to exclude sources of DHA from child's diet during the study~* Parent agrees not to give vitamins to child during the study~* English is the primary language in the home~* Signed Informed Consent and Protected Health Information~Exclusion Criteria:~* Gestational age at birth ≤ 36 weeks~* History of neuro/psychiatric conditions~* History of underlying metabolic or chronic disease~* Child is ill, has used antihistamines or diagnosed with an infection at time of cognitive testing~* History of suspected or known cow milk protein intolerance~* Child's diet contains sources of supplemental DHA more than one time per week~* Child is from a multiple birth and the sibling(s) are living in the same household~* Child is enrolled in another interventional clinical research study~* Use of antihistamines within 12 hours of cognitive testing

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 3 Years
- Healthy Volunteers: t

Study Arms:
- Milk-based beverage with DHA at mid-level (Type: EXPERIMENTAL): None
- Milk-based beverage with DHA at high level (Type: EXPERIMENTAL): None
- Milk-based beverage without DHA (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: HemaTrate™ in the Treatment of Critical Limb Ischemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Critical Limb Ischemia in the study leg with ischemic rest pain and/or ulcer/minor tissue loss (Rutherford 4 or 5)~2. Previously failed an endovascular or surgical treatment of the study lower leg and is not being considered for additional intervention within the next 3 months OR is unsuitable for revascularization~Exclusion Criteria:~1. Simultaneously participating in another investigational study (e.g., drug or device)~2. Pregnant or breastfeeding, or planning to become pregnant within the next 12 months~3. Major surgery (open cardiac, vascular, or abdominal procedure) within the past 90 days~4. Endovascular intervention within the past 30 days~5. Current dialysis, or expected to need dialysis within the next 12 months~6. Previous above the ankle amputation in the study leg

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Treatment Arm (Type: EXPERIMENTAL): Patients assigned to the treatment arm will be injected with autologous concentrated total nucleated cells (TNCs) three times at six week intervals.
- Saline (Control Arm) (Type: PLACEBO_COMPARATOR): Patients assigned to the control arm will be injected with saline three times at six week intervals.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Airway Secretion Clearance in Cystic Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* A proven diagnosis of CF as evidenced by a positive sweat test (as documented by a sweat chloride \>60 mEq/L by quantitative pilocarpine iontophoresis), or by the presence of two known CF mutations.~* Aged 7 or older.~* FEV1 \>45% (Knudson).~* Able to perform reproducible maneuvers for spirometry at screening as defined by the American Thoracic Society (ATS) and European Respiratory Society (ERS) guidelines.~* Willing to participate in and comply with the study procedures, and willingness of a parent or legally authorized representative to provide written informed consent.~Exclusion Criteria:~* Hospitalization for complications of CF, or a respiratory exacerbation resulting in - treatment with IV antibiotics within 60 days prior to screening.~* Use of any investigational drug or device within 60 days prior to screening.~* An episode of gross hemoptysis (\>249 ml) within 60 days prior to screening, or during the course of the study.~* A pneumothorax in the six months preceding the study or during the course of the study.~* Patients who are pregnant or become pregnant.~* Patients colonized with Burkholderia cepacia.

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 2 (Type: ACTIVE_COMPARATOR): None
- 3 (Type: ACTIVE_COMPARATOR): None
- 1 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pain Control in Elderly Hip Fracture Patients: Is Intravenous Acetaminophen Superior to Oral Administration?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Acute, isolated, unilateral femoral neck, intertrochanteric, and per trochanteric hip fractures confirmed by anteroposterior/lateral hip radiographs, computed tomography, or magnetic resonance imaging (MRI).~2. Age ≥ 65 years.~3. Low energy mechanism.~4. Hip fracture fixation performed within 48 hours of injury.~5. English speaking.~6. Anticipated medical optimization for operative fixation.~7. No other major trauma.~Exclusion Criteria:~1. Unable to provide informed consent (dementia, limited decision making capacity)~2. Admitted by medical service for significant co-morbidities~3. Retained hardware around the affected hip~4. Infection around the affected hip~5. Transfer patients with a length of stay \> 24 hours at the transferring hospital~6. Known allergy to acetaminophen~7. Current use of narcotics~8. Receiving a regional anesthetic block at any point during the hospitalization~9. Known history of hepatic disease (hepatitis, cirrhosis)~10. Weight \< 50kg~11. Prisoner~12. Involved in another clinical trial that would interfere with the intervention of this study

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PO Acetaminophen (Type: ACTIVE_COMPARATOR): 1,000mg Acetaminophen po every 8 hours until discharge.
- IV Acetaminophen (Type: EXPERIMENTAL): 1,000mg Acetaminophen IV every 8 hours until the patient has received 3 doses post-operatively. Then 1,000mg Acetaminophen po every 8 hours until discharge.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Video vs. Direct Laryngoscopy in Pediatric Nasal Intubation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients between the ages of 3 and 14 scheduled for comprehensive dental treatment under general anesthesia~* Normal appearing airway upon pre-operative assessment~Exclusion Criteria:~* Patient with a history of difficult airway/intubation~* Patients suspected to have a difficult airway~* History of cleft palate and/or cleft palate repair~* Pregnancy~* Emergency status of surgery~* Any patient with a contra-indication to nasal tube placement~* Any patient with a potentially increased risk of nasal bleeding from nasal placement of the ETT i.e. patients on aspirin or other anticoagulants, patient's with hemophilia

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 14 Years
- Healthy Volunteers: t

Study Arms:
- Direct Laryngoscopy (Type: ACTIVE_COMPARATOR): These patients will be nasally intubated for their procedure via direct laryngoscopy. We will observe and record incidence of Magill forcep use, presence or absence of nasal bleeding, and the grade of laryngeal view. We will also record any general narrative comments from the provider about the ease or difficulty of intubation.
- Video Laryngoscopy (Type: EXPERIMENTAL): These patients will undergo Video Laryngoscopy for nasal intubation. We will observe and record incidence of Magill forcep use, presence or absence of nasal bleeding, and the grade of laryngeal view. We will also record any general narrative comments from the provider about the ease or difficulty of intubation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Luveris In Vitro Fertilization Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 30 women under 38 years old at time of signing Informed Consent Form.~2. Evidence of hypothalamic amenorrhea (irregular menses and FSH and LH \<5 mIU/mL), uncorrected hyperprolactinemia (prolactin levels 10% above the upper limit of normal) or iatrogenic hypothalamic hypogonadism secondary to GnRHa suppression.~3. In good general health off of current medications which may confound response to study medications except GnRHa (Lupron Depot).~4. Desire to seek pregnancy actively during the study period.~5. A normal uterine cavity must have been confirmed by either hysteroscopy or hydrosonogram within two years of entering the study.~6. A semen analysis on the male partner deemed adequate for IVF by the attending physician within the past year or donor sperm available for insemination.~7. Only one treatment cycle per patient will be studied.~Exclusion Criteria:~1. uncorrected thyroid disease.~2. heart disease (New York Heart Association Class II or higher).~3. a history of, or suspected cervical, endometrial, or breast cancer. A normal Pap smear result within the last 24 months will be required.~4. enrolled into other studies that require medications, limit sex, or otherwise prevent compliance with the protocol at the same time.~5. to take other medications known to affect reproduction.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 38 Years
- Healthy Volunteers: f

Study Arms:
- Luveris Fixed dose (Type: ACTIVE_COMPARATOR): Participants in this arm will take Gonal F® and the same dose of Luveris® throughout the cycle. Their dose of Gonal F® will be adjusted throughout the cycle based on their response to the medication. The Luveris® dose will remain constant throughout.
- Luveris increasing dose (Type: EXPERIMENTAL): Patients assigned to this group will gradually reduce the Gonal F® dose while increasing the Luveris® dose during the cycle, which more closely mimics the natural menstrual cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Physician diagnosis of asthma for ≥6 months~* Pre-bronchodilator FEV1 of \>40% and \<80%~* History of treatment with corticosteroid or hospitalization for worsening asthma~* Medium- or high-dose inhaled corticosteroid use~Exclusion Criteria:~* History of smoking/vaping~* History of severe COVID~* Serious and/or uncontrolled pulmonary, cardiac, immune system conditions~* Requires systemic oral or IV corticosteroids in the month prior to screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- RPT193 400 mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Prehospital Cervical Ripening Before Induction and the Maternal Experience

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Intrauterine pregnancy~* Cephalic presentation~* Greater than 36 weeks estimated gestational age~* Reassuring fetal status~* Normal amniotic fluid index~* Clinical indication for induction of labor~Exclusion Criteria:~* Prior cesarean section~* Bishop score on cervical examination ≥ 6~* Unreliable transportation~* Home \> 30 minutes from the hospital~* Non-reassuring fetal status~* Abnormal amniotic fluid index~* Other indication for immediate hospitalization

- Gender: FEMALE
- Minimum Age: 15 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Usual Management (Type: NO_INTERVENTION): Patients in the usual management arm will have no pre-hospital cervical ripening and will undergo labor induction according to standard labor induction protocols on an inpatient basis.
- Outpatient transcervical Foley balloon (Type: EXPERIMENTAL): Patients in the experimental group will have a 30 cc transcervical Foley balloon placed in the outpatient setting approximately 12-18 hours prior to their labor induction. Once admitted, they will undergo inpatient labor induction as per usual protocols.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Relationship Between EBV and PTLD

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* patients undergone pediatric heart transplant~* followed by pediatric heart transplant program~Exclusion Criteria:~-

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Donor Eligibility Criteria:~* Age 18-60~* A history of a positive nasopharyngeal swab for COVID-19 or a history of positive titer test.~* At least 14 days from resolution of COVID-19-associated symptoms including fevers~* One negative nasopharyngeal swabs for COVID-19 RNA~* Covid-19 neutralizing antibody \>1:64~* Adequate venous access for apheresis~* Meets donor eligibility criteria in accordance to Hackensack University Medical Center (HUMC) Collection Facility at the John Theurer Cancer Center (JTCC) if collecting at the JTCC, and all regulatory agencies as describes in SOP 800 01 (Appendix A)~* Required testing of the donor and product must be performed in accordance to FDA regulations (21 CFR 610.40), and the donation must be found suitable (21 CFR 630.30)~Recipient Eligibility Criteria:~Recipients age \>18 years old, are assigned to one of two clinical tracks, track 2 or 3, based on COVID-19 disease severity. Onset of first symptoms \< 9 days.~Track 2:~* Hospitalized, moderate symptoms requiring medical care for COVID-19 infection~* Symptoms may include fever, dyspnea, dehydration among others~* Hypoxemia may be present but is not a requirement~Track 3:~* Requiring mechanical ventilation for the care of COVID-19 infection~* Requiring non-invasive positive pressure ventilation (NIPPV), such as continuous airway pressure (CPAP),bi-level positive airway pressure (BiPAP) or high flow nasal canula (HFNC).~Recipient exclusion criteria:~* History of severe transfusion reaction to plasma products~* Infusion of immune globulin within the previous 30 days~* AST or ALT \> 10 x upper limit of normal~* Requirement for vasopressors~* COVID-19-associated acute kidney injury requiring dialysis~* DNR status

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Convalescent Plasma (Type: EXPERIMENTAL): Fresh or frozen plasma will be infused one time to patients

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Enhanced Lung Protective Ventilation With ECCO2R During ARDS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* ARDS moderate or severe (Berlin criteria)~* Onset \< 48 h~* Driving pressure ≥ 11 cmH2O~Exclusion Criteria:~* Lack of consent or social protection~* Chronic respiratory failure (requiring Oxygen or NIPPV)~* Severe hypoxemia: PaO2/FIO2 \< 80 with PEEP ≥ 18 cmH2O AND FIO2= 1~* Acute Renal Failure requiring RRT~* DNR order or death expected within the next 72 hours~* Planned surgery or transport out-of-ICU expected within the next 72 hours~* Heparin allergy~* Contraindication to jugular vein catheterization~* Intracranial Hypertension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Minimal distension (Type: EXPERIMENTAL): Tidal volume 4 ml/kg PBW and positive end-expiratory pressure (PEEP) based on the ARDSNet PEEP/FiO2 table (ARMA) + ECCO2R (sweep gas = 8 L/min, blood flow = 400 mL/min)
- Maximal recruitment (Type: EXPERIMENTAL): Tidal volume 4 ml/kg PBW and PEEP adjusted to maintain a plateau pressure between 23 - 25 cmH2O + ECCO2R (sweep gas = 8 L/min, blood flow = 400 mL/min)
- Standard (Type: ACTIVE_COMPARATOR): Tidal volume 6 ml/kg PBW and positive end-expiratory pressure (PEEP) based on the ARDSNet PEEP/FiO2 table (ARMA) without ECCO2R (no sweep gas flow, blood flow = 400 mL/min)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues